Paratek expands commercial portfolio with Optinose

Paratek Pharmaceuticals has completed Optinose, approximately $ 330 million, and expanding its commercial products offers.

Companies signed a final integration agreement in March 2025.

PARATEK is now mainly antibiotics, nuzyra (omadacycline), and Optinose’s Xhance (Fluticasone ProPionate).

The acquisition includes all the shares owed to Optinose, including the assumption of debts and the payment of full value rights (CVRS).

Optinose shareholders agreed to integrate on May 16. The deal has been supported by Paratek, Novo Holdings and B-FLEXION LIFE Sciences, and debt financing from Oaktree Capital Management.

The shareholders received 9 dollars per share in cash and CVRS for up to $ 5 per share, and depends on Xhance to reach net revenue.

Paratek agreed to pay one dollar per share to collect XHance of $ 150 million in net sales in any evaluation year before December 31, 2028, and an additional $ 4 per share if it reached 225 million dollars before December 31, 2029.

Nuzyra is designed to combat tetracycline resistance and functions against a wide range of bacteria, including drug -resistant strains.

It is available in each of the formulas by mouth and vein to treat bacterial pneumonia gained from society and acute bacterial skin infections.

Xhance, a medication mix producer, uses exhale connectivity, which provides topical steroid to deep nasal cavity areas.

Evan Loh, CEO of Paratek Pharmaceuticals: “The addition of XHance to our portfolio is a focal first step in achieving our long -term vision to become a specialized multi -product treatment company, focusing on meeting important, unparalleled medical needs.

“This deal establishes a strong platform for us to continue taking advantage of these capabilities as we move forward to explore opportunities to expand our portfolio through acquisition of future products.”

Lazard, Skadden, ARPS, Slate and Meagher & Flom have provided exclusive financial and legal consulting services to Paratek.

Evercore and Hogan Lovells Us provided exclusive financial and legal advisory services for Optinose.

“Paraiatrics expands a commercial portfolio with Optinose” originally created and published by Pharmaceutical technologyThe brand owned by Globaldata.

Information on this site was included in good faith for public media purposes only. It is not intended to reach the advice that you should depend on, and we do not provide any representation, guarantee or guarantee, whether it is explicit or implicit in relation to accurately or completing it. You must have a professional or specialized advice before taking any action based on the content on our website.